Dr Lars Björnebo speaks to ecancer about a talk he presented at EAU 2022 about a novel risk prediction tool with standard biopsies vs PSA with MRI-targeted biopsies for prostate cancer screening.

He explains that a new model called the Stockholm-3 test could be used to skip the MRI step - something that would be very useful due to issues with availability.

Dr Björnebo reports that the study showed that the Stockholm-3 test found the same number of significant cancers as the PSA with MRI-targeted biopsies route.

However he notes that it does also flag some of the more insignificant cancers but that its still a good option and better than just using PSA followed by biopsies.